60
Participants
Start Date
July 30, 2025
Primary Completion Date
June 30, 2028
Study Completion Date
June 30, 2028
Vosoritide
The vosoritide dose administered will be based on the participant's weight and will follow the weight-band dosing regimen approved for ACH
Placebo
Subcutaneous injection of recommended dose of placebo
NOT_YET_RECRUITING
Royal Children's Hospital Melbourne, Parkville
NOT_YET_RECRUITING
IRCCS Istituto Giannina Gaslini, Genova
RECRUITING
Children's National Medical Center, Washington D.C.
NOT_YET_RECRUITING
The Johns Hopkins University School of Medicine, Baltimore
NOT_YET_RECRUITING
Universitätskinderklinik Magdeburg, Magdeburg
NOT_YET_RECRUITING
Uniklinik Köln, Cologne
NOT_YET_RECRUITING
Children's Wisconsin - Fox Valley Hospital, Neenah
NOT_YET_RECRUITING
University of Minneasota Masonic Children's Hospital, Minneapolis
NOT_YET_RECRUITING
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
NOT_YET_RECRUITING
University of Missouri, Columbia
NOT_YET_RECRUITING
Universitätsklinikum des Saarlandes, Homburg
NOT_YET_RECRUITING
Hospices Civils de Lyon - Hôpital Femme Mère Enfant, Bron
NOT_YET_RECRUITING
Phoenix Children's Hospital - Thomas Campus (Main), Phoenix
NOT_YET_RECRUITING
Cedars-Sinai Medical Center, Los Angeles
NOT_YET_RECRUITING
Hôpital Bicêtre, Le Kremlin-Bicêtre
NOT_YET_RECRUITING
Benioff Children's Hospital - Oakland, Oakland
NOT_YET_RECRUITING
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
NOT_YET_RECRUITING
Myriad Trials, London
NOT_YET_RECRUITING
Great Ormond Street Hospital, London
Lead Sponsor
Collaborators (1)
ICON Clinical Research
INDUSTRY
BioMarin Pharmaceutical
INDUSTRY